The Food and Drug Administration (FDA) on Thursday said it had tested a strain of chicken DNA for antibiotic resistance.
The company, BioMed Central Inc., said it was one of more than 150 samples from chickens in the U.S. that had been tested.
It said the strain of DNA, identified by the company as MDC-14, is the same as that found in the resistant strain of MDC used in human testing.
The FDA said it has not yet decided whether to approve BioMed’s MDC as a treatment for chicken disease.
BioMed said it is not the first company to test MDC and that other companies have used the same strain.
It has also been tested for its MDC for a few other types of chicken.
But BioMed has said the MDC is not a vaccine or treatment for human disease.
It is being used to develop a vaccine for a rare, life-threatening skin condition in chickens called MDC1.
“The FDA has been looking for new options to help the world address the problem of chicken disease, and we are very happy to be able to finally confirm this new MDC will be approved for human use,” said Matt Mott, a bioethics professor at the University of Wisconsin-Madison and BioMed vice president.
The new Mdc strain has been tested in humans and chickens, and is currently being evaluated for safety and efficacy.
BioLog also said the U:S.
Food and Drugs Administration has granted it a “priority review” for human clinical trials.
BioLab Diagnostics Inc., a subsidiary of BioMed, said the test results show that MDC can be a very effective and effective vaccine in humans.
“BioMed has shown that the Mdc gene can be used in animal models of human MDC infection and disease, but more importantly it can be administered to humans as a novel, human-targeted, biologic therapeutic agent for human MDA-1,” the company said in a statement.
BioMent Pharmaceuticals Inc., BioMed subsidiary, also said it hopes to begin clinical trials soon of its Mdc vaccine, which has not been approved by the FDA.
It did not immediately respond to requests for comment.
The agency did not give a timeline for the approval.
BioMart, which owns the chicken and egg businesses, is also looking for a vaccine candidate.
It was not immediately clear if the company had been granted a priority review.
Bio Med said the testing of Mdc is just the first step in a multi-stage clinical trial.
The next step, which is expected to start in the second quarter, will determine whether the vaccine will work in humans with chicken disease and whether it would be a good candidate for vaccine development.